Heart-Sparing Radiation for Stage 3 Lung Cancer
Part of Heart & circulation, Injuries & trauma clinical trials.
This study tests a new way of planning radiation therapy for stage 3 lung cancer. By carefully mapping the heart's structure, doctors aim to protect it from radiation and improve treatment safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC).
- Your cancer is stage 3, meaning it's locally advanced but hasn't spread far.
- You will receive radiation therapy at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan.
- You have not had radiation therapy to your chest before.
- You have not had heart surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to plan radiation for cancers in the chest area (like lung, esophageal, or thymus cancers) that aims to protect the heart from high doses of radiation. It is for people who need daily radiation for at least three weeks and who are expected to live more than a year.
This trial tests an early heart-focused intervention guided by a special heart recording (impedance cardiography) in people with locally advanced, unresectable stage III non-small cell lung cancer. The goal is to improve heart-related safety during planned radiation and chemotherapy, with or without immunotherapy.
This trial studies a treatment plan that combines chemotherapy, immunotherapy, and radiation to the chest for people with unresectable stage III non-small-cell lung cancer (NSCLC). It may help by delivering anti-cancer drugs while also shrinking tumors with targeted radiation, especially for people who are not able to have the standard “chemo and radiation at the same time.”
This study uses data from patients with early-stage lung cancer who received radiation therapy to learn how radiation affects the heart and lungs. The goal is to improve future treatments and reduce side effects.
This study tests a new combination of radiation therapy, an immunotherapy drug called tislelizumab, and chemotherapy for people with bulky stage III non-small cell lung cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This trial tests a new type of radiation (called SFRT) combined with chemotherapy and immunotherapy for people with stage 3 lung cancer that didn't shrink enough after standard treatment. The goal is to see if this combination can help improve the tumor response.
Hear when a new Locally Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.